■免疫检查点抑制剂(ICI)改善了不同癌症类型患者的总体生存率。然而,治疗效果因几个因素而异。最近的研究表明,抗生素诱导的生态失调会损害ICI的功效。在这里,我们回顾了抗生素使用对ICI治疗的胃肠道癌症患者临床结局的影响。
■这是一个系统的审查,并利用了MEDLINE的彻底搜索,科克伦,Scopus,EB-SCO,WebofScience的研究发表至2023年9月。该研究的目的是确定胃肠道癌症(GI)患者的抗生素使用与ICI治疗效果之间的关系。我们对抗生素使用与总生存期和无进展生存期之间的关系进行了荟萃分析。
■9项研究符合纳入标准,共有2,214例患者。最常见的癌症类型是肝细胞癌(HCC)。大部分研究都是回顾性的,一个是临床试验的集体。抗生素的使用与总生存期[haz-ard比值(HR)1.92,95%置信区间(CI)1.41,2.63]和无进展生存期[HR1.81,95%CI1.29,2.54]的降低相关。
抗生素的使用可能会影响ICI治疗的胃肠道肿瘤患者的临床预后。需要进一步的前瞻性研究来提高对这一现象的理解。
■https://www.crd.约克。AC.uk/prospro/display_record.php?ID=CRD42023462172。
UNASSIGNED: Immune checkpoint inhibitors (ICI) have improved overall survival in patients with different cancer types. However, treatment efficacy varies between patients depending on several factors. Recent research suggested that
antibiotic-induced dysbiosis can impair ICI efficacy. Here we
review the impact of
antibiotic use in clinical outcome of patients with gastrointestinal cancer treated with ICI.
UNASSIGNED: This is a systematic
review and utilized a thorough search of MEDLINE, Cochrane, Scopus, EB-SCO, Web of Science of studies published till September 2023. The aim of the study is to determine the association between
antibiotic use and ICI treatment efficacy in patients with gastrointestinal cancers (GI). We utilized a meta-analysis of the association between the use of antibiotics and overall survival and progression-free survival.
UNASSIGNED: Nine studies met the inclusion criteria with a total of 2,214 patients. The most common type of cancers was hepatocellular carcinoma (HCC). The majority of the studies were retrospective, and one was collective of clinical trials. The use of antibiotics was associated with decreased both overall survival [haz-ard ratio (HR) 1.92, 95% confidence interval (CI) 1.41, 2.63] and progression-free survival [HR 1.81, 95% CI 1.29, 2.54].
UNASSIGNED: The use of antibiotics may affect clinical outcomes in patients with GI cancers treated with ICI. Further prospective studies are needed to improve the understanding of this phenomenon.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023462172.